Loading, Please Wait...
Interim data for BPX-601 accepted for presentation at upcoming American Society of
Clinical Oncology (ASCO) Annual Meeting
Rivo-cel™ on-track for topline data readout from BP-004 pediatric trial in second quarter of 2019
HOUSTON, May 07, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported financial results for the first quarter 2019 and provided an operational update.
“We made strong progress in advancing our programs in the first quarter,” said Rick Fair, President and Chief Executive Officer of Bellicum Pharmaceuticals. “In our GoCAR-T® pipeline, we received acceptance of our abstract with new data from the BPX-601 Phase 1/2 clinical trial for the upcoming ASCO Annual Meeting, and made progress toward IND clearance and Phase 1 study start for BPX-603 later this year. In addition, we remain on track to announce topline results from the rivo-cel pediatric registrational trial by the end of the second quarter.”
PROGRAM HIGHLIGHTS AND CURRENT UPDATES
Controllable Dual-Switch GoCAR-T Product Candidates
First Quarter 2019 Financial Results
Cash Position and Guidance: Bellicum reported cash, restricted cash and investments totaling $78.1 million as of March 31, 2019, compared to $98.0 million at December 31, 2018. Based on current operating plans, Bellicum expects that current cash resources will be sufficient to meet operating requirements through the end of 2019. During the first quarter, Bellicum utilized its at the market financing facility selling 1.4 million shares for net cash proceeds of $4.6 million.
R&D Expenses: Research and development (R&D) expenses were $16.8 million for the first quarter of 2019, compared to $16.5 million for the first quarter of 2018. The higher expenses in the first quarter of 2019 resulted primarily from higher expenditures related to the GoCAR-T platform including initiation of additional clinical sites and costs related to IND filing.
G&A Expenses: General and administrative (G&A) expenses were $7.5 million for the first quarter of 2019 compared to $5.7 million during the comparable period in 2018. The higher expenses in the first quarter 2019 relative to the comparable period in 2018 were primarily due to increased personnel related costs due to hiring additional employees as well as increased costs related to commercialization preparation activities.
Net Loss: Bellicum reported a net loss of $24.5 million for the first quarter of 2019 compared to a net loss of $22.8 million for the first quarter of 2018. The results included non-cash, share-based compensation charges of $2.1 million and $3.6 million for the first quarter of 2019 and 2018, respectively.
Shares Outstanding: At April 30, 2019, Bellicum had 46,009,066 shares of common stock outstanding.
BPX-601, the company’s first GoCAR-T® product candidate, incorporates iMC, Bellicum’s inducible co-activation domain. iMC (inducible MyD88/CD40) is designed to provide a powerful boost to T cell proliferation and persistence and enable the CAR-T to override key immune inhibitory mechanisms, including PD-1 and TGF-beta. BPX-601 is being evaluated as a treatment for solid tumors expressing prostate stem cell antigen (PSCA), including pancreatic, gastric, and prostate cancers.
About Rivo-cel (BPX-501)
Rivo-cel™ (rivogenlecleucel) is an allogeneic polyclonal T-cell product designed to accelerate immune recovery after HSCT and to reduce relapse of leukemia following a stem cell transplant. The cell treatment contains a diverse repertoire of T cells which may contribute to a robust graft vs. leukemia effect. Rivo-cel’s anti-infective benefits may also reduce morbidity and mortality, as patients are highly susceptible to infection following a transplant. The product’s CaspaCIDe® safety switch enables this approach by allowing physicians to reduce the number of alloreactive cells in the event of uncontrolled GvHD. Rivo-cel addresses a major unmet need in adult and pediatric leukemia, lymphoma and inherited blood disease patients following a haploidentical stem cell transplant.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T and allogeneic T cell therapies. Bellicum’s lead GoCAR-T® candidate, BPX-601, is designed to be a more efficacious CAR-T cell product capable of overriding key immune inhibitory mechanisms. Bellicum’s rivo-cel product candidate is an allogeneic polyclonal T cell therapy that has shown promising clinical trial results in reducing leukemia relapse after a stem cell transplant. More information can be found at www.bellicum.com.
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Bellicum may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “designed,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things:
our research and development activities relating to rivo-cel, rimiducid, BPX-601, BPX-603, BPX-802, and other cell therapy programs; our pipeline candidates’ effectiveness, possible ranges of application and potential safety and curative effects in the treatment of diseases, including as compared to other treatment options and competitive therapies; the timing and success of our current and planned clinical trials, including the timing of receipt of data from such clinical trials and the timing of our reports of such data; the expansion of or changes to our ongoing clinical trials to new indications and diseases; the timing and success of regulatory filings for rivo-cel and rimiducid including our European Marketing Authorisation Applications (MAA); the speed and effectiveness of our preparations for potential commercialization in Europe if the MAAs are approved; and our cash uses and cash runway. Various factors may cause differences between Bellicum’s expectations and actual results as discussed in greater detail under the heading “Risk Factors” in Bellicum’s filings with the Securities and Exchange Commission, including without limitation our quarterly report on Form 10-Q for the three months ended March 31, 2019 and our annual report on Form 10-K the year ended December 31, 2018. Any forward-looking statements that Bellicum makes in this press release speak only as of the date of this press release. Bellicum assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
|BELLICUM PHARMACEUTICALS, INC.|
|Unaudited Condensed Consolidated Balance Sheets|
|March 31||December 31|
|Cash and cash equivalents||$||42,274||$||43,695|
|Investment securities, available-for-sale, short-term||31,210||49,304|
|Receivables and other current assets||3,201||2,296|
|Property and equipment, net||19,189||20,878|
|Accounts payable and other accrued liabilities||$||12,416||$||12,363|
|Other current liabilities||3,749||3,441|
|Other liabilities, net of current portion||41,143||37,219|
|Total Stockholders' Equity||50,860||68,478|
|Total Liabilities and Stockholders' Equity||$||108,168||$||121,501|
BELLICUM PHARMACEUTICALS, INC.
Unaudited Condensed Consolidated Statements of Operations
(in thousands, except share and per share amounts)
|Three Months Ended
|Research and development||16,818||16,536|
|General and administrative||7,536||5,692|
|Total operating expenses||24,384||22,258|
|Interest expense, net of interest income||(660)||(736)|
|Net loss attributable to common shareholders||$||(24,528)||$||(22,840)|
|Net loss per share attributable to common shareholders, basic and diluted||$||(0.55)||$||(0.68)|
|Weighted average common shares outstanding, basic and diluted||44,243,896||33,456,446|
Source: Bellicum Pharmaceuticals
Robert H. Uhl
Senior Vice President